• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on GRI Bio with a new price target

    12/9/24 7:50:37 AM ET
    $GRI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GRI alert in real time by email
    H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00
    Get the next $GRI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GRI

    DatePrice TargetRatingAnalyst
    12/9/2024$10.00Buy
    H.C. Wainwright
    More analyst ratings

    $GRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Kelly Leanne

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:28 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Chaturvedi Vipin

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:17 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Hertz Walter Marc

      4 - GRI Bio, Inc. (0001824293) (Issuer)

      1/24/25 5:58:06 PM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF")

      The Independent Data Monitoring Committee ("IDMC") has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the first 24 patients evaluated 6-week interim biomarker data (n=24) expected in July 2025 and topline data expected in Q3 2025 Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival LA JOLLA, CA, June 26, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovati

      6/26/25 8:00:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results

      Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621's potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from 6-week interim analysis (n=24) in ongoing Phase 2a study of GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis (IPF) anticipated in Q2 2025 LA JOLLA, CA, May 22, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the pr

      5/22/25 8:00:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio to Participate in the Virtual Investor Closing Bell Series

      Live webcast on Wednesday, May 28th at 4:00 PM ET LA JOLLA, CA, May 21, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio will participate in the Virtual Investor Closing Bell Series on Wednesday, May 28, 2025 at 4:00 PM ET. As part of the event, Dr. Hertz will provide a corporate overview and business outlook. In addition to the moderated discussion, investors and interested parties will have the opportunity to submi

      5/21/25 9:15:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on GRI Bio with a new price target

      H.C. Wainwright initiated coverage of GRI Bio with a rating of Buy and set a new price target of $10.00

      12/9/24 7:50:37 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    SEC Filings

    See more
    • GRI Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - GRI Bio, Inc. (0001824293) (Filer)

      6/26/25 8:01:08 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - GRI Bio, Inc. (0001824293) (Filer)

      5/23/25 7:16:47 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by GRI Bio Inc.

      424B5 - GRI Bio, Inc. (0001824293) (Filer)

      5/23/25 7:14:51 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GRI
    Leadership Updates

    Live Leadership Updates

    See more
    • Connect Biopharma Announces New Leadership and Chair of the Board of Directors

      Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cel

      6/12/24 4:15:00 PM ET
      $CNTB
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer

      - Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm LA JOLLA, CA, April 25, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of Natural Killer T ("NKT") cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced the appointment of Leanne Kelly as its Chief Financial Officer. Ms. Kelly is an accomplished financial executive with over 20 years of experience leading private and publicly traded companies across life science, technology and e-Commerce

      4/25/23 8:45:00 AM ET
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care